AlzeCure will host a breakfast seminar on Neuropathic Pain research, the orphan disorder Erythromelalgia, and our innovative clinical phase 2 therapeutic candidate, ACD440 on January 14 at the JP Morgan 2026 meeting in San Francisco. This meeting is the world’s leading lifescience partnering & investor meeting. We at AlzeCure are looking forward to present our company & the ACD440 project and meet with pharmaceuticals companies, partners & investors.
Hope to see you there.
Time: January 14 2026 at 8.00 – 8.45 am
Location: Business Sweden’s office at 100 Montgomery Street, floor 16, 94104 San Francisco
If you like to attend reach out to dimitrina.dimitrova@alzecurepharma.com before EOB 8 Jan.